EBNEO Commentary: Safety and immunogenicity of GBS vaccine in pregnancy and determination of a serocorrelate for infant protection
- PMID: 37950357
- DOI: 10.1111/apa.17038
EBNEO Commentary: Safety and immunogenicity of GBS vaccine in pregnancy and determination of a serocorrelate for infant protection
Comment on
-
Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.N Engl J Med. 2023 Jul 20;389(3):215-227. doi: 10.1056/NEJMoa2116045. N Engl J Med. 2023. PMID: 37467497 Clinical Trial.
References
REFERENCES
-
- Immunization, Vaccines and Biologicals. Accessed August 24, 2023. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases...
-
- Nakwa FL, Lala SG, Madhi SA, Dangor Z. Neurodevelopmental impairment at 1 year of age in infants with previous invasive group B streptococcal sepsis and meningitis. Pediatr Infect Dis J. 2020;39(9):794-798. doi:10.1097/INF.0000000000002695
-
- Madhi SA, Anderson AS, Absalon J, et al. Potential for maternally administered vaccine for infant group B streptococcus. N Engl J Med. 2023;389(3):215-227. doi:10.1056/NEJMOA2116045
-
- Puopolo KM, Lynfield R, Cummings JJ, COMMITTEE ON FETUS AND NEWBORN, COMMITTEE ON INFECTIOUS DISEASES. Management of infants at risk for group B streptococcal disease. Pediatrics. 2019;144(2):e20191881. doi:10.1542/peds.2019-1881
-
- Nogacka A, Salazar N, Suárez M, et al. Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome. 2017;5(1):93. doi:10.1186/S40168-017-0313-3
Publication types
LinkOut - more resources
Full Text Sources